1,121
Views
15
CrossRef citations to date
0
Altmetric
Letter to the Editor

Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2

ORCID Icon, , & ORCID Icon
Pages 5327-5333 | Received 28 May 2020, Accepted 11 Jun 2020, Published online: 24 Jun 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Subhadip Saha & Monidipa Ghosh. (2023) Computational exploration of natural compounds targeting Staphylococcus aureus: inhibiting AgrA promoter binding for antimicrobial intervention. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-12.
Read now

Articles from other publishers (14)

Mahshid Ataei, Omid Arasteh, Armin Salek Maghsoudi, Shokoufeh Hassani & Hesamoddin Hosseinjani. (2023) Therapeutic uses of Antihistamines in the Management of COVID-19: A Narrative Review. Anti-Infective Agents 21:2.
Crossref
Kaifu Gao, Rui Wang, Jiahui Chen, Limei Cheng, Jaclyn Frishcosy, Yuta Huzumi, Yuchi Qiu, Tom Schluckbier, Xiaoqi Wei & Guo-Wei Wei. (2022) Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Chemical Reviews 122:13, pages 11287-11368.
Crossref
Mohamed Fadlalla, Mazin Ahmed, Musab Ali, Abdulrhman A. Elshiekh & Bashir A. Yousef. (2022) Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models. Current Pharmacology Reports 8:3, pages 212-226.
Crossref
Biswa Mohan Sahoo, Subrat Kumar Bhattamisra, Sarita Das, Abhishek Tiwari, Varsha Tiwari, Manish Kumar & Sunil Singh. (2022) Computational Approach to Combat COVID-19 Infection: Emerging Tools for Accelerating Drug Research. Current Drug Discovery Technologies 19:3.
Crossref
Abhigyan Choudhury, Parth Sarthi Sen Gupta, Saroj Kumar Panda, Malay Kumar Rana & Suprabhat Mukherjee. (2022) Designing AbhiSCoVac - A single potential vaccine for all ‘corona culprits’: Immunoinformatics and immune simulation approaches. Journal of Molecular Liquids 351, pages 118633.
Crossref
Mohammad A. Elmorsy, Ahmed M. El-Baz, Nashwa H. Mohamed, Rafa Almeer, Mohamed M. Abdel-Daim & Galal Yahya. (2021) In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs. Environmental Science and Pollution Research 29:8, pages 12336-12346.
Crossref
Aaya Nassar, Ibrahim M. Ibrahim, Fatma G. Amin, Merna Magdy, Ahmed M. Elgharib, Eman B. Azzam, Filopateer Nasser, Kirllos Yousry, Israa M. Shamkh, Samah M. Mahdy & Abdo A. Elfiky. (2021) A Review of Human Coronaviruses’ Receptors: The Host-Cell Targets for the Crown Bearing Viruses. Molecules 26:21, pages 6455.
Crossref
Santenna Chenchula, Avik Ray & Balakrishnan Sadasivam. (2021) Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review. Drug Research 71:06, pages 295-301.
Crossref
Vikas Kumar, Shraddha Parate, Sanghwa Yoon, Gihwan Lee & Keun Woo Lee. (2021) Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2. Frontiers in Microbiology 12.
Crossref
AJ Al Mosawi. (2021) Famotidine Research Progress. Journal of Biomedical Research & Environmental Sciences 2:1, pages 021-023.
Crossref
Richard H. Hunt, James E. East, Angel Lanas, Peter Malfertheiner, Jack Satsangi, Carmelo Scarpignato & Gwilym J. Webb. (2021) COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. Digestive Diseases 39:2, pages 119-139.
Crossref
Madeleine Ennis & Katerina Tiligada. (2020) Histamine receptors and COVID-19. Inflammation Research 70:1, pages 67-75.
Crossref
Kenneth Alper. (2020) Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19. Frontiers in Medicine 7.
Crossref
Parth Sarthi Sen Gupta & Malay Kumar Rana. (2020) Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19. ACS Pharmacology & Translational Science 3:5, pages 1037-1038.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.